18:30 , May 11, 2018 |  BC Week In Review  |  Clinical News

Bioniz reports Phase Ib data for T cell malignancies candidate

Bioniz Therapeutics Inc. (Irvine, Calif.) reported data from a single-blind, placebo-controlled, U.S. Phase Ib trial in 25 healthy volunteers showing that multiple ascending doses of T cell malignancies candidate BNZ-1 led to no serious adverse...
16:48 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Bioniz reports Phase I safety data for BNZ-1

Bioniz Therapeutics Inc. (Irvine, Calif.) reported data from a Phase I trial in 18 healthy volunteers showing that single ascending doses of T cell malignancies candidate BNZ-1 were well tolerated with no serious adverse events...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
20:34 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Rheumatoid arthritis (RA) Patient sample and mouse studies suggest promoting IL-9 secretion by type 2 innate lymphoid cells (ILC2s) could help treat RA. In RA patients receiving anti-inflammatory therapy, IL-9 secretion shifted from lymphoid and...
07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

Cancer’s Phoenix

  Although recombinant IL-2 was a cancer immunotherapy long before checkpoint inhibitors came on the scene, the cytokine’s impact was limited by its potential for lethal side effects. Most attempts to lower toxicity also decreased efficacy....
07:00 , Aug 1, 2016 |  BC Extra  |  Financial News

Bioniz raises $13M in series A round

Bioniz Therapeutics Inc. (Irvine, Calif.) raised $13 million in a series A round co-led by the Takeda Ventures unit of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and David Pyott, the former chairman and CEO of Allergan...
07:00 , Oct 29, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Interleukin-9 (IL-9); (FCER1A)

Inflammation INDICATION: Allergy Mouse studies suggest inhibiting the production of IL-9-producing mucosal mast cells (MMC9s) could help treat IgE-mediated food allergy. In a mouse model of food allergy, intragastric ovalbumin challenge increased numbers of intestinal MMC9s, intestinal...
07:00 , Jul 17, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Inflammatory bowel disease (IBD) IL-9 Studies in human samples and mice suggest antagonizing IL-9 could help...
08:00 , Feb 27, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer IL-9 In vitro and mouse studies suggest adoptive transfer of IL-9-producing...
07:00 , Nov 1, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma IL-9 Mouse studies suggest IL-9-producing T helper type 9 (Th9) cells could help treat melanoma. In...